EMC8

Across TCGA pan-cancer cohorts, EMC8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EMC8 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EMC8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EMC8 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where EMC8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.210	0.778	.001	25	view →
HNSC	DFS	Tertile	All	1.000	0.272	.042	6	view →
CCRCC	DFS	Quartile	All	0.477	1.000	.023	2	view →
PDAC	OS	Median	III,IV	0.873	0.652	.019	1	view →
LSCC	DFS	Tertile	All	0.872	0.670	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EMC8–LUAD (OS)

Open the LUAD breakdown →